Methylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen)
Authors:
Open Access
- 20 April 2015
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 36 (5) , 627-643
Abstract
Aim: Tanshinol is an important catechol in the antianginal herb Salvia miltiorrhiza roots (Danshen). This study aimed to characterize tanshinol methylation. Methods: Metabolites of tanshinol were analyzed by liquid chromatography/mass spectrometry. Metabolism was assessed in vitro with rat and human enzymes. The major metabolites were synthesized for studying their interactions with drug metabolizing enzymes and transporters and their vasodilatory properties. Dose-related tanshinol methylation and its influences on tanshinol pharmacokinetics were also studied in rats. Results: Methylation, preferentially in the 3-hydroxyl group, was the major metabolic pathway of tanshinol. In rats, tanshinol also underwent considerable 3-O-sulfation, which appeared to be poor in human liver. These metabolites were mainly eliminated via renal excretion, which involved tubular secretion mainly by organic anion transporter (OAT) 1. The methylated metabolites had no vasodilatory activity. Entacapone-impaired methylation did not considerably increase systemic exposure to tanshinol in rats. The saturation of tanshinol methylation in rat liver could be predicted from the Michaelis constant of tanshinol for catechol-O-methyltransferase (COMT). Tanshinol had low affinity for human COMT and OATs; its methylated metabolites also had low affinity for the transporters. Tanshinol and its major human metabolite (3-O-methyltanshinol) exhibited negligible inhibitory activities against human cytochrome P450 enzymes, organic anion transporting polypeptides 1B1/1B3, multidrug resistance protein 1, multidrug resistance-associated protein 2, and breast cancer resistance protein. Conclusion: Tanshinol is mainly metabolized via methylation. Tanshinol and its major human metabolite have low potential for pharmacokinetic interactions with synthetic antianginal agents. This study will help define the risk of hyperhomocysteinemia related to tanshinol methylation.Keywords
This publication has 55 references indexed in Scilit:
- Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administrationBritish Journal of Pharmacology, 2013
- Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomesBritish Journal of Clinical Pharmacology, 2011
- Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory PotencyClinical Pharmacology & Therapeutics, 2010
- Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemiaActa Pharmacologica Sinica, 2010
- Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled TrialPLOS ONE, 2010
- Use of Herbal Products and Potential Interactions in Patients With Cardiovascular DiseasesJACC, 2010
- Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie”Drug Metabolism and Disposition, 2009
- Beneficial effects of danshensu, an active component of Salvia miltiorrhiza, on homocysteine metabolism via the trans‐sulphuration pathway in ratsBritish Journal of Pharmacology, 2009
- Qualitative Analysis of the Role of Metabolites in Inhibitory Drug−Drug Interactions: Literature Evaluation Based on the Metabolism and Transport Drug Interaction DatabaseChemical Research in Toxicology, 2009
- Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunctionLife Sciences, 2004